Skip to main content

Table 4 Plasma fatty acid composition in all subjects (A) and in the subgroup not prescribed EPA (B)

From: Effects of a novel nutritional formula specially developed for chronic kidney disease patients on protein-restricted diets: a randomized controlled trial

  SUP CTR
Variable 0 week 16 weeks 0 week 16 weeks
A. All subjects    
 EPA (μg/mL) 62.5 ± 37.0 85.8 ± 50.0*, *** 87.7 ± 76.9 87.0 ± 77.2
 DHA (μg/mL) 124.1 ± 63.8 149.9 ± 95.6 116.7 ± 52.9 118.4 ± 39.0
 ARA (μg/mL) 142.6 ± 45.5 142.0 ± 47.3 150.7 ± 57.8 149.4 ± 44.0
 α-Linolenic acid (μg/mL) 33.3 ± 17.2 39.0 ± 16.9* 31.6 ± 23.4 29.2 ± 12.9
 n-3/n-6 ratio 0.24 ± 0.09 0.30 ± 0.11*, *** 0.28 ± 0.17 0.26 ± 0.12
 EPA/AA ratio 0.47 ± 0.34 0.67 ± 0.51*, *** 0.72 ± 0.81 0.65 ± 0.62
B. Subgroup not prescribed EPA    
 EPA (μg/mL) 55.4 ± 34.4 75.6 ± 47.7*, *** 48.4 ± 27.3 43.7 ± 21.9
 EPA/AA ratio 0.36 ± 0.19 0.51 ± 0.26*, *** 0.31 ± 0.19 0.31 ± 0.20
  1. SUP supplement group, CTR control group (no supplement), EPA eicosapentaenoic acid, DHA docosahexaenoic acid, ARA arachidonic acid, EPA/AA eicosapentaenoic acid/arachidonic acid
  2. *P < 0.05 versus CTR, ***P < 0.01 versus 0 week